Long-term follow-up of second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction: three-year results of the XAMI trial

EuroIntervention 2015;10:1280-1283 published online ahead of print January 2015. DOI: 10.4244/EIJY15M01_03

Sjoerd H. Hofma1*, MD, PhD; Pieter C. Smits2, MD, PhD; Jan Brouwer1, MD, PhD; Matthijs A. Velders1, MD, PhD; Arnoud W.J. van ’t Hof3, MD, PhD; Michel Queré1, MD; Cornelis Jan de Vries1, MD; Adrianus J. van Boven1, MD, PhD

1. Medical Center Leeuwarden, Leeuwarden, The Netherlands; 2. Maasstad Hospital Rotterdam, Rotterdam, The Netherlands; 3. Isala Clinics, Zwolle, The Netherlands

Aims: Evaluation of the long-term safety and efficacy of second-generation everolimus-eluting stents (EES) versus first-generation sirolimus-eluting stents (SES) in acute myocardial infar

Forgot your password?

No account yet? Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

clinical researchprimary pcistemi

Share on Facebook Share on Twitter Share on Linkedin

Long-term follow-up of second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction: three-year results of the XAMI trial

Read next article

Latest news

Coronary

Valvular disease

Heart failure

Peripheral

Hypertension

Stroke